The Food and Drug Administration, in an attempt to ensure the safety of popular medicines, is partnering with one of the most prominent medical insurers in Massachusetts. It has awarded a contract for up to $150 million to Harvard Pilgrim Health Care Institute a collaboration between Harvard Pilgrim Health Care and Harvard Medical School to spearhead a program that sifts through billions of prescriptions and other electronic health care data to investigate issues with FDA-approved drugs. Richard Platt, head of the Department of Population Medicine and professor of population medicine, is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?